Technology
Alterity Therapeutics to commercialise technology that breaks antibiotic resistance – Small Caps
The University of Queensland’s commercial vehicle UniQuest has granted a licence allowing Alterity Therapeutics (ASX: ATH) to use its zinc ionophore technology…
The University of Queenslands commercial vehicle UniQuest has granted a licence allowing Alterity Therapeutics (ASX: ATH) to use its zinc ionophore technology in combating superbugs.
UniQuest has given Alterity exclusive worldwide rights to use its zinc ionophore technology in developing and commercialising therapies that re-sensitise bacteria to antibiotics.
Once Alterity has begun receiving commercial revenue from commercialising the technology, it will make milestone and royalty payments to UniQuest…
-
General20 hours agoOf saints and sinners | The Spectator Australia
-
General20 hours agoChina and Philippines trade blame over latest South China Sea clash
-
Noosa News24 hours agoBrisbane rising on global rankings, but still behind southern capitals
-
General20 hours agoSmall plane crashes into San Diego neighbourhood, setting homes and vehicles on fire